NIH R01 · 2024
Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.
Project Summary/Abstract Vaccination is a potent regulator of the immune system and much research is being conducted to understand how antigen-specific stimulation can be used to induce and redirect anti-tumor immunity. Our team develops a cancer immunotherapy program using novel AAV vectors to deliver antigens both directly and by cross- presentation to antigen presenting cells. Optimization of naturally occurring AAV serotypes and novel methods of AAV production are necessary to warrant wide use of these vectors for cancer immunotherapy. The main aims of this proposal is to determine the safety and efficacy of our novel AAV-based vaccines as part of preclinical studies by using companion…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.